Company intelligence / Profile preview

Steritas

Concord, Massachusetts, United States

Ownership: Private
Employees: ~41
Development stage: Other

Overview

Steritas’s STOX Suite is the first validated system for measuring steroid-toxicity, broadly adopted globally in clinical trials and at the point of care; data from >1100 sites in 80+ countries, 25+ indications; supports drug development for steroid-sparing therapeutics

Therapeutic areas: ImmunologyNephrologyOphthalmologyPsychiatryInfectious DiseasesRare DiseasesDermatologyNeurologyWomen's Health
Modalities: Digital clinical outcome assessment
Industry: Digital Health Medical Devices

Partnerships

argenx (Immunology therapeutics; STOX Suite used across argenx’s immunology clinical trials for steroid-sparing therapies)

Beyond the preview

Go deeper on Steritas.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Steritas.

Explore the full profile